• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 21, 2016

View Archived Issues

In the clinic

Portage Biotech Inc., of Toronto, said its Biohaven unit started dosing subjects in the first study testing the pharmacokinetics and safety of BHV-4157. Read More

Other news to note

Synaffix BV, of Amsterdam, said preclinical studies showed that its platform technologies, Glycoconnect and Hydraspace, generated antibody drug conjugates (ADCs) with improved therapeutic index in comparison to the ADCs Kadcyla (trastuzumab emtansine, Genentech Inc./Roche Group) and Adcetris (brentuximab vedotin, Seattle Genetics Inc.), approved by the FDA to treat HER2-positive breast cancer and multiple lymphoma indications, respectively. Read More

Financings

Ablynx NV, of Ghent, Belgium, said an additional 39,818 common shares have been issued in exchange for €160,489 (US$176,860) as the result of the exercise of warrants. Read More

Regulatory front

Viracor-Ibt Laboratories Inc., of Lee's Summit, Mo., received emergency use authorization from the FDA for its Zika virus real-time RT-PCR assay. Read More

Ireland agrees to new drug pricing framework with pharma industry

DUBLIN – In the smoke-and-mirrors world of drug pricing in Europe, Ireland is claiming a little victory on foot of a new drug pricing agreement with the pharmaceutical industry which will help to keep a lid on rising drug prices between now and 2020. Read More

Solid debut for gene therapy firm Audentes after pricing $75M IPO

In another promising sign for the gene therapy space, shares of Audentes Therapeutics Inc. received an encouraging welcome on Wall Street Wednesday after the San Francisco-based firm priced a $75 million IPO, offering 5 million shares at $15 each, the midpoint of its proposed range. Read More

Tuberculosis is getting attention; will new vaccines, drugs follow?

DURBAN, South Africa – "When people learn that tuberculosis is airborne, that it kills millions of people, that drug resistance is spreading, watch their reaction – they do not think that TB is boring anymore," Jose Luis Castro, executive director of the International Union Against Tuberculosis and Lung Disease, told the audience at the 2016 international AIDS conference. Read More

Precision Ocular lands £15.5M to develop more precise eye drugs, delivery

LONDON – Precision Ocular Ltd. closed a £15.5 million (US$20.4 million) series A funding that will enable it to take the first of new generation of low-dose, slow-release retinal drugs from preclinical research and into the clinic. Read More

Zafgen punts to follow-on MetAP2 candidate after beloranib bust

Zafgen Inc. scrapped plans to develop its lead candidate, beloranib, after deciding the road forward would be too long and costly, based on FDA feedback, following two patient deaths in its phase III bestPWS trial in Prader-Willi syndrome (PWS). Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe